NULISA Analytical Performance (Stanford)
BRD ID: 3,344
Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 7
Description
This assay analytical validation and performance report describes the procedures used by the Cancer Immune Monitoring and Analysis Center (CIMAC) at Stanford for the analysis of 250 cytokines using Nucleic acid Linked Immunosorbent Assay (NULISA). The document presents data generated using serum specimens from COVID-19 patients and healthy controls that support the reported accuracy, precision, analytical sensitivity and specificity of the assay. Data is shown to support the use of serum specimens after one or two freeze-thaw cycles. Comparisons with the Olink Target96 and Luminex H80 assays are presented for shared targets. It is a product of the CIMAC and Cancer Immunologic Data Center (CIMAC-CIDC Network; https://dctd.cancer.gov/ResearchNetworks/cimacs_cidc_network.htm), a Cancer Moonshot Initiative.
Documents for Download
508C_NULISA validation doc KA_20240916_clean_final.pdf [Size: 3424 KB]Biospecimens
- Fluid - Serum
Diagnoses
- General
- Pneumonia/Respiratory Infection
Topics
- Platform-specific Methodology
Associated SOP Compendiums
- Platform-specific Methodology